Mental disorders and the state of the blood-brain barrier in patients with the new coronavirus infection
Suggested citation:
Kekelidze ZI, Gurina OI, Shport SV, et al. [Mental disorders and the state of the blood-brain barrier in patients with the new coronavirus infection]. Rossiiskii psikhiatricheskii zhurnal [Russian Journal of Psychiatry]. 2021;(6):22-32. Russian
An open prospective study to determine the clinical features of mental disorders in patients with the new coronavirus infection and its connection with the permeability of the blood-brain barrier included 97 patients hospitalized in connection with COVID-19 of varying severity, but without signs of mental disorders in the anamnesis. Somatoform, neurotic and depressive disorders of mild or moderate severity were detected in 45.4% of cases, however, a number of patients (13.4%) had severe degree of disorders, including those with pronounced suicidal ideation. During the immunochemical study, an increase of the level of neurospecific proteins (GFAP and NSE) in blood serum has been detected, however, no reliable correlation of psychopathological symptoms with the results of the analysis of neurospecific proteins could be detected at the present stage. It is assumed that when the blood-brain barrier is permeated, a direct toxic effect on the nervous tissue makes such an oppressive impact that it prevents the development of structurally complex psychopathological formations.
Keywords mental disorders; blood-brain barrier; new coronavirus infection; SARS-CoV2
1. Benedetti F, Palladini M, Paolini M, et al. Brain correlates of depression, post-traumatic distress, and inflammatory biomarkers in COVID-19 survivors: A multimodal magnetic resonance imaging study. Brain Behav Immun Health. 2021;18:100387. DOI: https://doi.org/10.1016/j.bbih.2021.100387 2. Desforges M, LeCoupanec A, Dubeau P, et al. Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system? Viruses. 2019;12(1):1–28. DOI: https://doi.org/10.3390/v12010014 3. Maury A, Lyoubi A, Peiffer-Smadja N, et al. Neurological manifestations associated with SARS-CoV-2 and other coronaviruses: A narrative review for clinicians. Rev Neurol (Paris). 2021;177(1–2):51–64. DOI: https://doi.org/10.1016/j.neurol.2020.10.001 4. Pilotto A, Masciocchi S, Volonghi I, et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Encephalitis Is a Cytokine Release Syndrome: Evidences From Cerebrospinal Fluid Analyses. Clin Infect Dis. 2021;73(9):e3019–26. DOI: https://doi.org/10.1093/cid/ciaa1933 5. Wood H. New insights into the neurological effects of COVID-19. Nat Rev Neurol. 2020;16(8):403. DOI: https://doi.org/10.1038/s41582-020-0386-7 6. Zubair AS, McAlpine LS, Gardin T, et al. Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019: A Review. JAMA Neurol. 2020;77(8):1018–27. DOI: https://doi.org/10.1001/jamaneurol.2020.2065 7. De Lorenzo R, Loré NI, Finardi A, et al. Blood neurofilament light chain and total tau levels at admission predict death in COVID-19 patients. J Neurol. 2021;268(12):4436–42. DOI: https://doi.org/10.1007/s00415-021-10595-6 8. Frithiof R, Rostami E, Kumlien E, et al. Critical illness polyneuropathy, myopathy and neuronal biomarkers in COVID-19 patients: A prospective study. Clin Neurophysiol. 2021;132(7):1733–40. DOI: https://doi.org/10.1016/j.clinph.2021.03.016 9. Kanberg N, Ashton NJ, Andersson LM, et al. Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19. Neurology. 2020;95(12):e1754–9. DOI: https://doi.org/10.1212/WNL.0000000000010111 10. Kanberg N, Simrén J, Edén A, et al. Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up. EBioMedicine. 2021;70:103512. DOI: https://doi.org/10.1016/j.ebiom.2021.103512 11. Chekhonin VP, Gurina OI, Dmitrieva TB. Monoklonal'nye antitela k neirospetsificheskim belkam. Moscow: Meditsina; 2007. 344 р. (In Russ.) 12. Huebschmann NA, Luoto TM, Karr JE, et al. Comparing Glial Fibrillary Acidic Protein (GFAP) in Serum and Plasma Following Mild Traumatic Brain Injury in Older Adults. Front Neurol. 2020;11:1054. DOI: https://doi.org/10.3389/fneur.2020.01054 13. Olsson B, Lautner R, Andreasson U, et al. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15(7):673–84. DOI: https://doi.org/10.1016/S1474-4422(16)00070-3 14. Thelin E, Al Nimer F, Frostell A, et al. A Serum Protein Biomarker Panel Improves Outcome Prediction in Human Traumatic Brain Injury. J Neurotrauma. 2019;36(20):2850–62. DOI: https://doi.org/10.1089/neu.2019.6375 15. Abrahamson EE, Ikonomovic MD. Brain injury-induced dysfunction of the blood brain barrier as a risk for dementia. Exp Neurol. 2020;328:113257. DOI: https://doi.org/10.1016/j.expneurol.2020.113257 16. Ganti L, Serrano E, Toklu HZ. Can Neuron Specific Enolase Be a Diagnostic Biomarker for Neuronal Injury in COVID-19? Cureus. 2020;12(10):e11033. DOI: https://doi.org/10.7759/cureus.11033 17. Cione E, Siniscalchi A, Gangemi P, et al. Neuron-specific enolase serum levels in COVID-19 are related to the severity of lung injury. PLoS One. 2021;16(5):e0251819. DOI: https://doi.org/10.1371/journal.pone.0251819
DOI: http://dx.doi.org/10.47877/1560-957Х-2021-10603
Article Metrics
Metrics powered by PLOS ALM